Jún 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics a GenScript ProBio sú v procese podpisovania zmluvy na vývoj a výrobu plazmidových a vírusových vektorov pre prvý reťazec platformy Advanced CAR-T (platforma ACT) ACT Therapeutics, ktorá bude tiež poverená výrobou surovín. pre následné potrubia ACT Therapeutics. Zmluva bude pokrývať produkciu plazmidov a vírusových vektorov pre prvý reťazec platformy Advanced CAR-T od ACT Therapeutics.
V dôsledku tejto dohody bol GenScript ProBio povýšený na globálneho partnera, ktorý je schopný podporovať ACT platformy pre ACT terapeutiká.
Platforma ACT je technológia bunkovej a génovej terapie novej generácie, ktorá sa zameriava na rakovinové antigény vložením génov určených na zacielenie týchto antigénov do imunitných buniek. Tieto gény sa dostávajú do imunitných buniek pomocou vírusových vektorov. GenScript ProBio disponuje vysoko kvalitným vývojom vírusových vektorových procesov a komplexnou platformou služieb pre produkciu GMP, ktoré sú potrebné pre vývoj bunkovej a génovej terapie.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing rakovina krvi. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, generálny riaditeľ spoločnosti GenScript ProBio, povedal: „Sme veľmi radi, že môžeme spolupracovať s ACT therapeutics v strategickom partnerstve a tešíme sa na podporu platformy ACT Therapeutics ako globálneho partnera prostredníctvom našej nahromadenej technológie.“
Seogkyoung-Kong, generálny riaditeľ ACT Therapeutics, povedal: „Dokončili sme prípravy na to, aby sa platforma ACT objavila globálne prostredníctvom strategického partnerstva s GenScript ProBio. Urýchlime vývoj liečebných postupov zameraných na refraktérne a neliečiteľné solídne rakoviny.“
O GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
K poslaniu „Inovácie prostredníctvom spolupráce“ sa GenScript ProBio zaviazal pomáhať zákazníkom skrátiť časovú os pre vývoj biologických liekov od objavu po komercializáciu, výrazne znížiť náklady na výskum a vývoj a vybudovať zdravšiu budúcnosť.
